Revvity, Inc. Company Analysis & Research
Revvity is an American company in the life sciences and diagnostics business focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health.
The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023, marking a transformation aimed at strengthening its market position as a translational solutions provider. Revvity serves pharmaceutical and biotech, clinical labs, academia, and governments worldwide.
Company Overview
Founded: 1937. Headquarters: Waltham, Massachusetts. Revenue: $2.86B. Market Cap: $11.8B. Ticker: RVTY (NYSE).
Industry
Life Sciences and Diagnostics
Cyborg Score: 7/10 — Strong
Well-positioned translational life sciences platform with strong diagnostics revenue stream; attractive consolidation target given recent operational efficiency improvements and strategic rebranding.
With a market capitalization of $11.8B and trailing twelve month revenue of $2.86B, Revvity demonstrates solid financial performance. The company benefits from a broad customer base across pharma, diagnostics, and academic research, though it faces intense competition from larger diversified life sciences players.
Key Strategic Insights for Revvity, Inc.
- Q4 2025 earnings beat analyst expectations, with analysts boosting forecasts following the results
- Recent acquisition of ACD/Labs completed in November 2025 demonstrates continued strategic portfolio expansion
- Medical diagnosis equipment represents 54.5% of revenue while analytical tools and instruments comprise 45.5%, providing balanced diversification
- Significant geographic diversity with US at 39.8%, China at 16.3%, UK at 4.1%, and other regions at 39.8% of revenue
Recent Developments
- (Feb 2026) Q4 2025 earnings beat expectations with analyst forecast upgrades
- (Nov 2025) Acquisition of ACD/Labs to expand software and data management capabilities
- (2025) Continued operational efficiency improvements and portfolio optimization initiatives
Competitors & Competitive Landscape
- Thermo Fisher Scientific — Analytical instrumentation and research tools
- Agilent Technologies — Life sciences and diagnostics instrumentation
- Danaher Corporation — Laboratory automation and detection technologies
- Abbott Laboratories — Newborn screening and prenatal diagnostics
- Roche Holding — In vitro diagnostics and testing solutions
In life sciences, Revvity competes with Thermo Fisher Scientific, Agilent Technologies, and Danaher Corporation in analytical instrumentation, imaging systems, and laboratory automation. In diagnostics, the company faces competition from Abbott Laboratories, Roche Holding, and Siemens Healthineers in newborn screening and prenatal testing.
More Company Research
Acanthe Développement SE Ekopak NV Gooch & Housego PLC Euroseas Ltd. TROOPS, Inc. Zee Entertainment Enterprises Limited Donnelley Financial Solutions Dr. Soliman Abdel Kader Fakeeh Hospital Company Frasers Logistics & Commercial Trust Land Securities Group PLC Trina Solar Co., Ltd. Surgutneftegas Public Joint Stock Company International Flavors & Fragrances Inc. PAO NOVATEK EdenrobeFull Company Research Reports
Looking for a more in-depth analysis of Revvity, Inc.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.